Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours

被引：0
|
作者：
Faidon-Marios Laskaratos
Martin Walker
Keval Naik
Emmanouil Maragkoudakis
Nikolaos Oikonomopoulos
Lee Grant
Tim Meyer
Martyn Caplin
Christos Toumpanakis
机构：
[1] Centre for Gastroenterology,Department of Infectious Disease Epidemiology
[2] Neuroendocrine Tumour Unit,Department of Radiology
[3] Centre for Gastroenterology,undefined
[4] Royal Free Hospital NHS Foundation Trust,undefined
[5] School of Public Health,undefined
[6] Faculty of Medicine,undefined
[7] Imperial College London,undefined
[8] Royal Free Hospital NHS Foundation Trust,undefined
[9] UCL Cancer Institute,undefined
[10] University College London,undefined
来源：
British Journal of Cancer | 2016年 / 115卷
关键词：
octreotide LAR; neuroendocrine tumours; antiproliferative activity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1321 / 1327
页数：6
相关论文
共 50 条
  • [21] Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head-to-head study
    Auriemmal, R. S.
    Pivonello, R.
    Galdiero, M.
    De Martino, M. C.
    De Leo, M.
    Vitale, G.
    Lombardi, G.
    Colao, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008, 31 (11) : 956 - 965
  • [22] Peptide Receptor Radionuclide Therapy as First Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumours
    Satapathy, Swayamjeet
    Sood, Ashwani
    Sood, Apurva
    Mittal, Bhagwant
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [23] Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey
    Falconi, Massimo
    Fazio, Nicola
    Ferone, Diego
    Versari, Annibale
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (18) : 2317 - 2324
  • [24] Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head- to- head study
    R. S. Auriemma
    R. Pivonello
    M. Galdiero
    M. C. De Martino
    M. De Leo
    G. Vitale
    G. Lombardi
    A. Colao
    Journal of Endocrinological Investigation, 2008, 31 : 956 - 965
  • [25] Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors
    Satapathy, Swayamjeet
    Mittal, Bhagwant Rai
    Sood, Ashwani
    Sood, Apurva
    Kapoor, Rakesh
    Gupta, Rajesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (09) : E393 - E399
  • [26] First-line therapy of advanced chronic lymphocytic leukemia
    Wilhelm, M
    Tony, HP
    RueckleLanz, H
    Wilms, K
    LEUKEMIA, 1997, 11 : S14 - S18
  • [27] Selection of First-Line Therapy for Advanced Follicular Lymphoma
    Press, Oliver W.
    Palanca-Wessels, Maria Corinna
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (12) : 1496 - 1498
  • [28] New first-line therapy for advanced breast cancer
    Schwetz, BA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (09): : 1146 - 1146
  • [29] Bevacizumab as first-line therapy for advanced breast cancer
    Bartsch, R.
    de Vries, C.
    Foedermayr, M.
    Mader, R. M.
    Huber, M.
    Bago-Horvath, Z.
    Pluschnig, U.
    Steger, G. G.
    Dubsky, P.
    Fitzal, F.
    Schreil, G.
    Zielinski, C. C.
    Gampenrieder, S. P.
    Ziebermayr, R.
    ONKOLOGIE, 2010, 33 : 16 - 16
  • [30] FIRST-LINE MEDICAL THERAPY IN ADVANCED METASTATIC RCC
    Porta, Camillo
    Giglione, Palma
    Lombardo, Fiorella
    Paglino, Chiara
    ANTICANCER RESEARCH, 2014, 34 (10) : 6117 - 6118
12345